A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Príomhchruthaitheoir: | Karim, Azrin |
---|---|
Rannpháirtithe: | Islam, Farzana |
Formáid: | Project report |
Teanga: | English |
Foilsithe / Cruthaithe: |
Brac University
2024
|
Ábhair: | |
Rochtain ar líne: | http://hdl.handle.net/10361/24372 |
Míreanna comhchosúla
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
de réir: Islam, Saidul
Foilsithe / Cruthaithe: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
de réir: Ahmed, Nafisa
Foilsithe / Cruthaithe: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
de réir: Meem, Manila
Foilsithe / Cruthaithe: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
de réir: Hossain, Sadman Sanjid
Foilsithe / Cruthaithe: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
de réir: Jahan, Nusrat
Foilsithe / Cruthaithe: (2024)